Figures
- FIGURE 1
Main respiratory toxicities linked to immunotherapy.
- FIGURE 2
Comparison between three studies: severity grade and radiological patterns. OP: organising pneumoniae; HSP: hypersensitivity pneumonitis; NSIP: non-specific interstitial pneumoniae; GGO: ground-glass opacities; ARDS: acute respiratory distress syndrome. #: Common Terminology Criteria for Adverse Events 4:0.
- FIGURE 3
Suggested “decision tree” for interstitial lung disease induced by immune-checkpoint inhibitors (ICI) treatment. CT: computed tomography. #: progressive cancer lesions, infection, pulmonary embolism or heart failure.
- FIGURE 4
Suggested management according to severity grade. Grade 1: asymptomatic, clinical or diagnostic observation only; intervention not indicated; Grade 2: symptomatic, medical intervention indicated; limiting instrumental activities of daily living; Grade 3: severe symptoms; limiting self-care activities of daily living, oxygen indicated; Grade 4: life-threatening respiratory compromise; urgent intervention indicated (e.g. tracheotomy or intubation). #: a disorder characterised by inflammation focally or diffusely affecting the lung parenchyma.
- FIGURE 5
Interstitial lung disease induced by immune-checkpoint inhibitors improvement after treatment. OP: organising pneumoniae; HSP: hypersensitivity pneumonitis.
Tables
- TABLE 1
Comparison between the three studies
Study Naidoo et al. [7] Nishino et al. [8] Delaunay et al. [6] Cases n 43 20 64 Histology 26 Melanoma 10 Melanoma 13 Melanoma 9 NSCLC 4 NSCLC 48 NSCLC 4 Haematological malignancies 6 Lymphoma 1 Lymphoma 1 Bladder carcinoma 2 Head and neck carcinoma 1 Breast carcinoma 1 Pancreatic carcinoma 1 Head and neck carcinoma Incidence 5% 11.8% 3.5% Time to pneumonitis onset 2.8 months (9 days to 19.2 months) 2.6 months (0.5–11.5) 2.3 months (0.2–27.4) Data presented as median (range), unless otherwise stated. NSCLC: nonsmall cell lung cancer.
Jump To
- Article
- Abstract
- Abstract
- Introduction
- What is the incidence of pulmonary toxicity associated with ICI treatment?
- Can we forecast or predict pulmonary toxicity?
- How to diagnose ILD associated with ICI treatment?
- How to treat ILD-ICI
- Can we re-challenge patients with immunotherapy following lung toxicity?
- Other pulmonary toxicities
- What is the impact of immune-related adverse events on patient outcomes?
- Organisation
- Conclusion
- Footnotes
- References
- Figures & Data
- Info & Metrics